Skip to main content
Clinical Trials/NL-OMON52836
NL-OMON52836
Recruiting
Phase 2

Sleep positional therapy for the treatment of nocturnal gastroesophageal reflux - LEFT

Academisch Medisch Centrum0 sites45 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
gastroesophageal reflux disease
Sponsor
Academisch Medisch Centrum
Enrollment
45
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Written informed consent.
  • Age above 18 years.
  • Symptoms of heartburn and/or acid regurgitation at least 2 times a week
  • during the night.
  • A total reflux symptom score \>\=8 (measured through the GERDQ questionnaire
  • Minimal of 1\.5% esophageal acid exposure during the night.

Exclusion Criteria

  • Surgery of the GI tract other than appendectomy or cholecystectomy.
  • Use of any medication with a potential effect on gastrointestinal motility,
  • secretion or sensitivity that cannot be stopped for the duration of the study
  • (e.g. H2\-blockers, antidepressants, prokinetics, antacids).
  • History of gastrointestinal cancer.
  • Known diabetes.
  • Regular use of sleep medication (benzodiazepines) that cannot be stopped.
  • Severe and clinically unstable concomitant disease (e.g. liver,
  • cardiovascular or lung disease, neurological or psychiatric disorders, cancer
  • or AIDS and other endocrine disorders).

Outcomes

Primary Outcomes

Not specified

Similar Trials